Werewolf Therapeutics, Inc. reports $11.9 million Q1 loss

Werewolf Therapeutics, Inc. [HOWL] has reported fiscal Q1 loss of $11.90 million.

On a per-share basis, the DE based company said its diluted earnings are $0.34.

The Pharmaceutical Preparations firm posted revenue of $4.40 million in this period.